WO2024118094A1 - Système et méthode pour la prévention de l'alopécie - Google Patents

Système et méthode pour la prévention de l'alopécie Download PDF

Info

Publication number
WO2024118094A1
WO2024118094A1 PCT/US2022/080540 US2022080540W WO2024118094A1 WO 2024118094 A1 WO2024118094 A1 WO 2024118094A1 US 2022080540 W US2022080540 W US 2022080540W WO 2024118094 A1 WO2024118094 A1 WO 2024118094A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
hair
composition
synephrine
agonist
Prior art date
Application number
PCT/US2022/080540
Other languages
English (en)
Inventor
Ofer A. Goren
Original Assignee
Follea International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Follea International filed Critical Follea International
Priority to PCT/US2022/080540 priority Critical patent/WO2024118094A1/fr
Publication of WO2024118094A1 publication Critical patent/WO2024118094A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/415—Aminophenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18

Definitions

  • the present invention is directed to methods for treating, reducing or preventing alopecia and other hair loss disorders caused by mechanical pulling of the hair, including but not necessarily limited to traction alopecia, and compositions, devices and kits useful in such methods.
  • Traction alopecia results from the chronic application of tensile force to scalp hair (1).
  • the condition was described as early as 1907 in subjects from Greenland who had developed hair loss due to prolonged wearing of tight ponytails (2).
  • traction alopecia has been related to specific hairstyles that cause increased tension on the scalp (e.g., ponytails, Afro-Caribbean hair styles with tight braiding or the tightly wound turbans of Sikh men). It has also been seen in female ballerinas. It is also seen in cultural traditions where the hair is voluntarily not cut in religious obeisance, which causes progressively increasing weight of the hair itself.
  • Traction alopecia is mechanical in etiology, rather than androgenic. Management includes cessation of the chronic traction. However, this is unacceptable to people who favor the specific hairstyles and styling techniques that give rise to the condition.
  • Traction alopecia is a substantial risk in hair extensions and weaves, which can be worn either to conceal hair loss, or purely for cosmetic purposes. The latter involves creating a braid around the head below the existing hairline, to which an extended-wear hairpiece, or wig, is attached. Because the hair of the braid is still growing, it requires frequent maintenance, which involves the hairpiece being removed, the natural hair braided again, and the piece snugly reattached. The tight braiding and snug hairpiece cause tension on the hair that is already at risk for falling out. Traction alopecia is one of the most common causes of hair loss in African American women.
  • Traction alopecia includes hair loss or shedding due to increased traumatic force on hair follicles caused by hairstyle or mechanical hair procedures such as blow drying, flat ironing, hair curling and chronic brushing. Traction alopecia can also develop in patients constantly pulling their hair such as in trichotillomania. [0004] In traction alopecia, affected areas depend on the etiology of the disorder, but usually hair loss is localized on frontal and temporal scalp. According to population studies in African women, prevalence of traction alopecia varies from 17.1% in young women (6-21 years) to 31.7% in older women (18-86 years).
  • traction alopecia Clinical features of traction alopecia include itching of the scalp, perifollicular erythema, scaling, folliculitis, and pustules, but it can also present as slow onset of hair loss without other symptoms.
  • traction alopecia is considered noncicatricial, yet excessive tension can lead to permanent alopecia, due to physical damage of hair follicles. Prolonged force on hair follicles may lead to inflammatory changes in immune cell infiltrate and fibrosis can result. Therefore, it is important to recognize the condition early, while it is still reversible.
  • compositions and methods are disclosed herein for the treatment and prevention of hair loss disorders caused at least in part by repeated application of tensile force to hair, including, without limitation, traction alopecia.
  • Such disorders may be treated or prevented by the application to the hair follicle or scalp of a compound or agent that induces contraction of the arrector pili (AP) muscle, such as, without limitation, alpha 1 adrenergic receptor agonists (A1AR agonists) and/or trace amine associated receptor agonists (TAAR agonists).
  • AP arrector pili
  • A1AR agonists alpha 1 adrenergic receptor agonists
  • TAAR agonists trace amine associated receptor agonists
  • Embodiments relate to a method for treatment or of traction alopecia comprising applying a composition comprising a pilomotor effective amount of a combination of synephrine and tyramine, or a pharmaceutically acceptable salt or hydrate thereof, topically to a portion of skin on the head that includes at least one hair follicle to increase the epilatory force threshold of the at least one hair follicle.
  • the at least one hair follicle is under tension.
  • the portion of skin is at risk for developing traction alopecia.
  • the synephrine is present in the composition in a concentration of 5% by weight and the tyramine is present in the composition in a concentration of 2% to 4% by weight.
  • the composition comprises the 1 -enantiomer of synephrine that is R-(-)-4-[l-hydroxy-2-(methylamino)ethyl]phenol and has less than 5% by weight of other enantiomers of synephrine.
  • R-(-)-4-[l-hydroxy-2-(methylamino)ethyl]phenol is present in the composition at 1% to 4% by weight.
  • Embodiments relate to a method of reducing hair shedding during brushing, combing or showering, the method comprising applying a composition comprising a pilomotor effective amount of a combination of synephrine and tyramine, or a pharmaceutically acceptable salt or hydrate thereof, topically to a portion of skin on the head that includes at least one hair follicle to increase the epilatory force threshold of the at least one hair follicle.
  • composition of the pilomotor effective amount of the combination of synephrine and tyramine is applied to the skin prior to the brushing or combing.
  • the at least one hair follicle is under tension.
  • the synephrine is present in the composition in a concentration of 5% by weight and the tyramine is present in the composition in a concentration of 2% to 4% by weight.
  • the composition comprises the 1 -enantiomer of synephrine that is R-(-)-4-[l-hydroxy-2-(methylamino)ethyl]phenol and has less than 5% by weight of other enantiomers of synephrine.
  • Embodiments relate to a method for increasing epilatory force threshold of the hair, the method comprising applying a composition comprising a pilomotor effective amount of a combination of synephrine and tyramine, or a pharmaceutically acceptable salt or hydrate thereof, topically to a portion of skin on the head of a person that includes at least one hair follicle to increase the epilatory force threshold of the at least one hair follicle.
  • the person before, during or after the composition is applied, the person undergoes a cosmetic procedure to the hair selected from the group consisting of braiding, flat ironing, attaching a hair weave, attaching a hair extension, or tying the hair back in a ponytail.
  • the synephrine is present in the composition in a concentration of 5% by weight and the tyramine is present in the composition in a concentration of 2% to 4% by weight.
  • the composition comprises the 1 -enantiomer of synephrine that is R-(-)-4-[l-hydroxy-2-(methylamino)ethyl]phenol and has less than 5% by weight of other enantiomers of synephrine.
  • R-(-)-4-[l-hydroxy-2-(methylamino)ethyl]phenol is present in the composition at 1% to 4% by weight.
  • composition of the pilomotor effective amount of the combination of synephrine and tyramine, or a pharmaceutically acceptable salt or hydrate thereof is applied to the skin once daily.
  • composition of the pilomotor effective amount of the combination of synephrine and tyramine, or a pharmaceutically acceptable salt or hydrate thereof is applied to the skin twice daily.
  • Embodiments relate to a method for treating traction alopecia comprising: applying a composition comprising a pilomoter effective amount of a combination of synephrine and tyramine, or a pharmaceutically acceptable salt or hydrate thereof, to the scalp to an area with a group of follicles that will experience a pulling force from a hair augmentation device to increase the epilatory force threshold of the group of follicles; and attaching the hair augmentation device to the group of follicles.
  • the method comprises applying the composition to cause a hair of the at least one hair follicle to stand up and/or to cause puckering of the skin around a shaft of the hair.
  • the method comprises applying the composition to cause puckering of the skin around a shaft of a hair of the at least one hair follicle.
  • the method comprises applying the composition to cause puckering of the skin around a shaft of a hair of the at least one hair follicle.
  • the method comprises comprising applying the composition to cause puckering of the skin around a shaft of a hair of the at least one hair follicle.
  • Figure 1A depicts a cross sectional view of the hair follicle and the arrector pili muscle in a relaxed state
  • Figure IB depicts a cross sectional view of the hair follicle and the arrector pili muscle in a tensed state.
  • Figures 2 and 3 depict hair loss from mechanical pulling according to the experiment reported in example 3.
  • Figures 4 and 5 depict epilatory force thresholds on scalp hair follicles following topical phenylephrine application according to the procedures described in example 3.
  • Each hair follicle in the scalp contains an arrector pili muscle that, when contracted, erects the hair.
  • the smooth muscle in the arrector pili expresses al adrenergic receptors (“Al AR”) and trace amine associated receptors (“TAAR”).
  • Al AR al adrenergic receptors
  • TAAR trace amine associated receptors
  • topical administration to the scalp or hair follicle of a composition comprising one or more TAAR agonists and/or one or more Al AR agonists.
  • such agonists protect against hair loss or shedding as shown by an increase in epilation force needed to remove a hair and reduction in the number of hairs removed after brushing.
  • the compounds and agents used in the present invention stimulate contraction of the AP muscle and thereby reduce hair loss by increasing the force required to remove the hair.
  • Al AR agonists to promote the pilomotor effect is described in U.S. 4,853,216, which is incorporated herein by reference in its entirety. There, the A1AR agonists were recognized as useful for causing hairs to stand up to facilitate closer shaving or to potentiate the effect of depilatories. That is, Al AR agonists were described there as agents that facilitate hair removal, as opposed to prevent hair loss.
  • traction alopecia means a form of alopecia (hair loss or hair shedding) associated with mechanical forces that pull the hair such as hair brushing hair combing, flat ironing, wearing of extensions, hair braiding, and ponytail style hair. Under this definition, although chronic traction on the hair can lead to traction alopecia, the mechanical forces that pull the hair do not necessarily need to be chronic to lead to hair loss or excessive shedding.
  • the term “pilomotor effective” refers to an agent or treatment that stimulates contraction of the arrector pili muscle associated with a hair follicle.
  • a “pilomotor effective amount” of an agent or treatment is an amount sufficient to stimulate contraction of the arrector pili muscle.
  • alpha 1 adrenergic receptor agonist refers to a ligand that binds the alpha 1 adrenergic receptor on smooth muscle cells and activates smooth muscle contraction.
  • trace amine associated receptor agonist refers to a ligand that binds the trace amine associated receptor on smooth muscle cells and activates smooth muscle contraction. Additionally, the term “trace amine associated receptor agonist” can include agents that when applied will induce the release of endogenous trace amine associated receptor agonists (e.g. tyramine) that activates smooth muscle contraction or agents that when applied inhibit the "re-uptake” or degradation of endogenous trace amine associated receptor agonists (e.g. tyramine) that activates smooth muscle contraction.
  • endogenous trace amine associated receptor agonists e.g. tyramine
  • endogenous trace amine associated receptor agonists e.g. tyramine
  • a ligand that in addition to binding to the TAAR is a norepinephrine (NE) releasing agent, e.g.., known to cause the release of NE, which activates smooth muscle contraction.
  • NE norepinephrine
  • a “smooth muscle agonist” is an agent that promotes or results in contraction of the smooth muscle, and such agents are specifically contemplated for use in the methods and compositions described herein.
  • a trace amine associated receptor agonist that promotes or results in smooth muscle contraction is a smooth muscle agonist, but so also are, e.g., an alpha 1 adrenergic receptor agonist or an alpha 2 adrenergic receptor agonist that promotes smooth muscle contraction, agents that that induce the release of endogenous alpha 2 adrenergic receptor agonist that results in smooth muscle contraction, and agents that inhibit the re-uptake or degradation of endogenous alpha 2 adrenergic receptor agonists that activate smooth muscle contraction.
  • embodiments of the methods disclosed herein can involve application of a composition that will cause contraction of the smooth muscle mediated by a trace amine associated receptor agonist.
  • Other smooth muscle agonists are known in the art and/or discussed herein below (see, e.g., section below headed "Other agents or approaches to contract the smooth muscle.”).
  • the terms “prevent” or “prevention” and other derivatives of the words when used in reference to alopecia, e.g., traction alopecia, refer to a reduced likelihood of alopecia in an individual receiving a given treatment relative to that of a similar individual at risk for alopecia but not receiving that treatment.
  • the terms “prevent” and “prevention” encompass a treatment that results in a lesser degree of alopecia, e.g., traction alopecia, than would be otherwise expected for a given individual.
  • Efficacy for prevention of alopecia can be established through controlled studies, e.g., in which a subject is administered a treatment (e.g., a topical treatment) at one site likely to experience or exhibit alopecia (e.g., for traction alopecia, a site at which hair is pulled for an extended period of time) but not at another site subjected to the same conditions.
  • a treatment e.g., a topical treatment
  • alopecia e.g., for traction alopecia, a site at which hair is pulled for an extended period of time
  • the site treated with the topical treatment undergoes less hair loss over time relative to the untreated site, e.g., at least 5% less, at least 10% less, at least 15% less, at least 20% less, at least 25% less, at least 30% less, at least 35% less, at least 40% less, at least 45% less, at least 50% less or beyond, the treatment is effective for the prevention of alopecia, e.g., traction alopecia.
  • alopecia e.g., traction alopecia.
  • Efficacy for the prevention of other forms of alopecia can be established in a similar manner, e.g., by treating one area affected by or likely to be affected by such alopecia, but not another, substantially similar area (e.g., subject to the same conditions causing alopecia or a likelihood of alopecia) and comparing hair loss or retention in the two areas.
  • the terms “treat,” “treatment,” or “treating” refer to therapeutic treatments, wherein the object is to reverse, alleviate, ameliorate, inhibit, slow down or stop the progression or severity of a disease or condition, e.g., traction alopecia or other form of alopecia.
  • the term “treating” includes reducing or alleviating at least one adverse effect or symptom of a disease or condition, e.g., traction alopecia or other form of alopecia.
  • Treatment is generally “effective” if one or more symptoms are reduced. Alternatively, treatment is “effective” if the progression of a disease is reduced or halted.
  • treatment includes not just the improvement of symptoms, but also a cessation of, or at least slowing of, progress or worsening of symptoms compared to what would be expected in the absence of treatment.
  • Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (e.g., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, remission (whether partial or total), and/or decreased mortality.
  • treatment is considered effective if the extent or amount of hair loss is reduced, or the progression of hair loss is slowed or halted.
  • treatment also includes providing relief from the symptoms or side-effects of the disease (including palliative treatment).
  • the term “epilatory” relates to the removal of hair.
  • the term “increasing epilatory force” refers to any treatment that increases the physical force required to remove a hair.
  • the increase in force can be viewed as at least a partial balancing of a traction force by the force exerted by the arrector pili muscle - the vector direction of the arrector pili muscle’s force of contraction need not necessarily be directly opposed to a traction force on the hair shaft to increase the epilatory force required to remove the hair, but the net effect is that the muscle provides at least a partial counter-acting force to the traction force, whether it directly pulls back on the hair or simply holds the hair or hair follicle more tightly in place.
  • An increase in epilatory force can be measured in several ways, including empirically, through a reduction in traction alopecia (e.g., 10% or less reduction in hair loss) despite continued or ongoing traction, or through measurement of actual force exerted on the hair follicle, e.g., with a myograph, trichotilometer, or a device used to measure tensile forces.
  • compositions, methods, etc. refers to component(s) or method steps that are present in the method or composition, yet allows for the composition, method, etc. to also include unspecified elements.
  • Consisting essentially of refers to those elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment.
  • the technology described herein relates to the prevention of traction alopecia.
  • One preventive approach currently available for traction alopecia is to remove, limit or avoid the application of a traction force to the hair.
  • hairstyles or other factors that pull on the hair should normally be avoided to prevent traction alopecia.
  • a TAAR agonist in combination with an Al AR agonist (e.g., a combination of a TAAR agonist and an Al AR agonist) to the hair follicle or scalp
  • an Al AR agonist e.g., a combination of a TAAR agonist and an Al AR agonist
  • This preventive approach permits one to wear a hairstyle, helmet, etc., that would normally have a high risk of inducing traction alopecia without actually suffering the traction- related hair loss.
  • TAAR agonists when applied to the hair follicle or scalp alone and not in combination with any other agonists, have been shown to limit, reduce or prevent the traction alopecia-inducing effects of hairstyles or other factors that pull on the hair despite the ongoing traction involved.
  • Application of a composition including a TAAR agonists (e.g., tyramine) alone and not in combination with any other agonists may require a concentration of 10% by weight or more of the TAAR agonist.
  • a TAAR composition including a TAAR agonist in a concentration of at least 10%, without any Al AR agonists included in the TAAR composition has been shown to elicit a clinical response in a plurality patients.
  • A1AR agonists when applied to the hair follicle or scalp alone and not in combination with other agonists, have been shown to limit, reduce or prevent the traction alopecia-inducing effects of hairstyles or other factors that pull on the hair despite the ongoing traction involved.
  • Application of a composition including an Al AR agonist (e.g., synephrine) alone and not in combination with any other agonists may require a concentration of 30% by weight or more of the A1AR agonist.
  • an A1AR composition including an A1AR agonist in a concentration of at least 30%, without any TAAR agonists included in the Al AR composition has been shown to elicit a clinical response in a plurality of patients.
  • compositions including a TAAR agonist e.g., tyramine
  • a composition including an Al AR agonist e.g., tyramine
  • an Al AR agonist e.g., tyramine
  • compositions including a concentration of a TAAR agonist of less than 10% by weight and/or including a concentration of an Al AR agonist of less than 30% by weight would fail to elicit any response from one or more patients.
  • TAAR agonist and an A1AR agonist in a composition for the purpose of eliciting a pilomotor reflex of a hair arrector-pili muscle to treat and/or prevent disorders associated with mechanical stress or pulling on the hair.
  • Non-limiting embodiments disclosed herein demonstrate that a combined composition of a TAAR agonist and an Al AR agonist reduces the required concentrations of the TAAR agonist and the A1AR agonist in a composition (e.g., below a concentration of 10% by weight TAAR agonist and below a concentration of 30% by weight Al AR agonist) for eliciting a pilomotor reflex of a hair arrector-pili muscle.
  • a composition may include a composition that includes a TAAR agonist in a concentration of less than 10% by weight and an A1AR agonist in a concentration of less than 30% by weight.
  • a combined composition of a TAAR agonist and an A1AR agonist may include a TAAR agonist in a concentration of about 2% to about 5% by weight and an A1AR agonist in a concentration of about 5% by weight.
  • pilomotor stimulation Various aspects of the technology described herein involve pilomotor stimulation.
  • the measurement or detection of pilomotor stimulation can be performed, at its simplest, by observation of the area at the base of the hair shaft - an agent or treatment that induces arrector pili contraction causes the hair follicle to “stand up” and causes puckering of the skin around the hair shaft commonly referred to as “goose bumps.”
  • an agent or treatment that induces arrector pili contraction causes the hair follicle to “stand up” and causes puckering of the skin around the hair shaft commonly referred to as “goose bumps.”
  • the agent has stimulated the arrector pili.
  • Measurement of the strength of arrector pili muscle contraction can be performed, if necessary, via myograph adapted for that purpose.
  • Tri chotillom etry the reliability and practicality of hair pluckability as a method of nutritional assessment.
  • Tri chotillom etry the quantitation of hair pluckability as a method of nutritional assessment. Am J Clin Nutr 1981 : 34(10): 2280-2286.
  • Traction alopecia is a form of alopecia, or gradual hair loss, caused primarily by pulling force applied to the hair.
  • Several different hair styles and hair extensions can cause or exacerbate traction alopecia.
  • certain styles or braiding patterns that pull the hairline have been shown to cause traction alopecia.
  • Particularly tight braids, barrettes, or the installation of hair extensions can exert sufficient chronic force on the hair follicles to cause traction alopecia.
  • traction alopecia has a mechanical origin based on the force on the hair.
  • each follicular unit contains a smooth muscle anchoring the hair to the epidermis.
  • the smooth muscle When the smooth muscle is relaxed as illustrated in Figure 1A, the muscle does not supply much restraining force and the follicle can be removed easily.
  • the smooth muscle or arrector pili contracts as illustrated in Figure IB, the follicle stands up and is restrained by additional force from the smooth muscle rather than just primarily the surrounding connective tissue of the dermis. Accordingly, the smooth muscle can provide more retention force in opposition to a force that would pull on the hair to dislodge the follicle if it is contracted.
  • the arrector pili (AP) muscle by contracting the arrector pili (AP) muscle, the root can be more firmly grounded into the dermis of the skin preventing the mechanical strain from damaging the root and dermis, e.g., requiring a larger epilation force for removal of the hair follicle. This would prevent the chronic stressing from pulling of the hair observed in different hairstyles from doing as much damage to the root, and thereby would prevent or reduce the risk of developing traction alopecia.
  • the technology described herein relates to the reduction of the force exerted on the root of a hair.
  • this “reduction” in force is more akin to providing a better balancing force against a traction on the hair itself - that is, the treatments described herein will not necessarily reduce the amount of traction on the hair, but by stimulating the contraction of the arrector pili muscles, the treatments provide a force that at least partially counters the effect of the traction or pulling force, thereby protecting the root against the epilatory effect of the traction.
  • a pharmaceutical composition containing a combination of a TAAR agonists and an A1AR agonist e.g., a composition containing a concentration of a TAAR agonist and a concentration of an A1AR agonist
  • electrical stimulation of the hair follicles e.g., electrical stimulation of the hair follicles and others.
  • the invention concerns treating, reducing or preventing hair loss from disorders such as traction alopecia, androgenic alopecia (also known as androgenetic alopecia), alopecia areata, and alopecia universalis, and hair loss due to hair brushing, combing, etc. comprising topical administration to a person in need thereof of a therapeutically effective amount of a combination of a TAAR agonist and an A1AR agonist.
  • disorders such as traction alopecia, androgenic alopecia (also known as androgenetic alopecia), alopecia areata, and alopecia universalis, and hair loss due to hair brushing, combing, etc.
  • the invention concerns a method for the reduction of the force exerted on a root of a hair comprising topical administration to a person in need thereof of a therapeutically effective amount of a combination of a TAAR agonist and an A1AR agonist.
  • the invention concerns a method for increasing hair epilation force comprising topical administration to a person in need thereof of a therapeutically effective amount of a combination of a TAAR agonist and an A1AR agonist.
  • the invention concerns a cosmetic method for piloerecting hair or raising hair comprising topical administration to a person in need thereof of a therapeutically effective amount of a combination of a TAAR agonist and an Al AR agonist.
  • the therapeutically effective amount of the agent administered is a pilomotor effective amount.
  • the therapeutic agent such as the combination of the TAAR agonist and the Al AR agonist, is applied to a skin section, such as a section of the scalp, that contains at least one hair follicle.
  • the at least one hair follicle is under tension.
  • Combinations of TAAR agonists and Al AR agonists may be administered to the hair follicle or scalp to promote contraction of the AP muscle and thereby reduce, treat or prevent alopecia and the other disorders discussed herein. It is specifically contemplated that a combination of a TAAR agonist and an A1AR agonist or any other agonist of smooth muscle contraction known in the art or disclosed herein can be administered to the hair follicle or the scalp in combination with an agent that retards systemic absorption of the agent across the dermis. In this manner, agents that might otherwise have unwanted systemic effects can be used to treat, reduce or prevent alopecia or other disorders discussed herein while avoiding such systemic side effects.
  • agents for topical administration in a manner that avoids systemic absorption is discussed in detail in U.S. 2009/0068287, which is incorporated herein by reference in its entirety.
  • a method for prevention of traction alopecia comprising: applying a therapeutically effective amount, such as a pilomotor effective amount, of a combination of a TAAR agonist and an Al AR agonist to the scalp to an area with a group of follicles that will experience a pulling force from a hair augmentation device; and attaching the hair augmentation device to the group of follicles.
  • the hair augmentation device is a hair extension or extensions.
  • the hair augmentation device is a weave.
  • the hair augmentation device is a barrette.
  • a therapeutically effective amount such as a pilomotor effective amount
  • a combination of a TAAR agonist and an Al AR agonist topically to a portion of skin that includes at least one hair follicle.
  • the combination of the TAAR agonist and the A1AR agonist is present on a brush or comb that may then be used to administer the therapeutic agent such as the combination of the TAAR agonist and the A1AR agonist.
  • the combination of the TAAR agonist and the Al AR agonist is applied to the skin prior to the brushing or combing.
  • the cosmetic procedure is selected from the group consisting of brushing, braiding, flat ironing, and combinations of two or more thereof.
  • the therapeutic agent such as the combination of the TAAR agonist and the A1AR agonist, may be topically applied once, twice, or more often per day.
  • the combination of the TAAR agonist and the Al AR agonist is applied to the skin twice daily.
  • the combination of the TAAR agonist and the Al AR agonist is applied to the skin prior to the cosmetic procedure.
  • a method for treatment of trichotillomania comprising applying a pilomotor effective amount of a combination of a TAAR agonist and an A1AR agonist topically to a portion of skin that includes at least one hair follicle.
  • the disclosure also concerns evaluating an individual for susceptibility to treatment according to the methods disclosed herein.
  • the method comprises (1) applying a combination of a TAAR agonist (e.g., without limitation, tyramine) and an Al AR agonist (e.g., without limitation, synephrine) on a site on the skin of a person; and (2) 30 to 60 minutes after applying, observe whether the person’s skin shows goosebumps or pilioerection at the site; wherein if pilioerection or goosebumps are observed, diagnosing the person as likely to be a successful candidate for use of the combination of the trace amine associated receptor agonist and the alpha 1 adrenergic receptor agonist for any of the many methods of treatment or prevention described herein.
  • a TAAR agonist e.g., without limitation, tyramine
  • Al AR agonist e.g., without limitation, synephrine
  • the step of application to the skin may be, in one embodiment, applying a bandage or patch coated with the combination of the trace amine associated receptor agonist and the alpha 1 adrenergic receptor agonist to the person’s arm or thigh.
  • the TAAR agonist is tyramine and the AIAR agonist is synephrine or phenylephrine.
  • the therapeutic agents particularly the combination of the TAAR agonists and the AIAR agonists, described herein and used in the present methods may be formulated into compositions according to the knowledge of one of skill in the art.
  • the combination of the TAAR agonist and the AIAR agonist or other stimulator of AP muscle contraction is formulated for topical slow or prolonged release.
  • the AP stimulating agent is encapsulated for slow release and integrated into a hair extension.
  • the combination of the TAAR agonist and the A1AR agonist or other stimulator of AP muscle contraction is formulated in a shampoo (which can reduce hair shedding during hair brushing), a foam, ointment, spray, solution, gel, slow release capsule, oral tablet, or any similar compound or delivery vehicle or methodology.
  • Topical application is preferred.
  • the composition is formulated in a topical cream.
  • the composition is formulated in a hair styling product selected from the group consisting of a styling gel, a styling foam, and a hair conditioner.
  • the composition may comprise an exfoliating agent to promote abrasion of the surface of the scalp.
  • exfoliating agent include (1) inorganic and/or metallic particles such as: boron nitride, in body-centered cubic form (Borazon®); aluminosilicate (e.g.
  • nepheline zircon
  • mixed oxides of aluminum such as emery; zinc oxide; aluminum oxides such as aluminas or corundum; titanium oxide; titanium oxide coated mica; carbides, in particular silicon carbide (carborundum); or other metal oxides; metals, and metal alloys such as iron shot, steel shot, and in particular perlite; silicates such as glass, quartz, sand, or vermiculite; calcium carbonate (e.g. Bora-Bora sand or Rose de Brignoles sand) or magnesium carbonate; sodium chloride; pumice stone; amorphous silica; diamond; ceramics, and (2) organic particles such as: fruit stones, in particular apricot stones, e.g.
  • Scrubami® apricot wood cellulose, e.g. ground bamboo stem; coconut shell, e.g. coconut exfoliator; polyamides, in particular Nylon- 6; sugars; plastic microbeads, e.g. polyethylenes or polypropylenes; ground walnut; ground apricot seed; ground shells, and (3) mixed particles associating organic and inorganic compounds, and particles coated in the above compounds.
  • the exfoliating agents may be in the form of microbeads of less than five millimeters in its largest dimension that have an exfoliating effect.
  • the composition comprising a combination of a TAAR agonist and an Al AR agonist can be formulated as a drug. In one embodiment, the composition comprising a combination of a TAAR agonist and an Al AR agonist can be formulated as a cosmetic product.
  • the AP muscle can be contracted via electrical stimulation to the scalp.
  • the stimulation can be controlled by a battery and control unit embedded into a hair extension, or in, e.g., a hair brush or comb.
  • the control unit can contain an accelerometer to detect the optimal time to contract the AP muscles based on the posture of the subject or the subject’s hair.
  • the amount of therapeutic agent present in the composition may be determined by one of skill in the art using known methodologies.
  • the TAAR agonist, the A1AR agonist, or other stimulator of AP muscle contraction is present in the composition in a concentration from about 0.20% to 0.30%, or about 0.25% by weight.
  • the therapeutic agent such as a TAAR agonist and/or an Al AR agonist is present in the composition in a concentration of about 0.25%, 0.33%, 0.5%, 1%, 2%, 2.5%, 3%, 4%, 5%, or 10% by weight.
  • the therapeutic agent such as the Al AR agonist
  • the topical composition for use in the methods disclosed herein in a concentration from about 0.1% to 35%, about 1.0% to 30%, about 0.2% to 30%, about 0.2% to 25% , about 0.2% to 20%, about 0.2% to 15%, about 0.2% to 10%, about 0.2% to 5%, about 0.2% to 4%, about 0.2% to 3%, about 0.2% to 2%, about 0.2% to 1%, about 10.0% to 30%, about 15.0% to 30%, about 20.0% to 30%, about 10% to 20%, about 10% to 15%, about 15% to 20%, about 15% to 60%, about 20% to 60%, about 50% to 60%, and about 45% to 55% by weight.
  • a concentration of about 0.1% to 5%, 25% to 60%, 30% to 50%, 30% to 60%, 25% to 30%, 40% to 50%, or 50% to 55% by weight of the total weight of the composition is desirable.
  • the therapeutic agent such as the TAAR agonist
  • the topical composition for use in the methods disclosed herein in a concentration from about 0.1 % to 35%, about 1.0% to 30%, about 0.2% to 30%, about 0.2% to 25%, about 0.2% to 20%, about 0.2% to 15%, about 0.2% to 10%, about 0.2% to 5%, about 0.2% to 4%, about 0.2% to 3%, about 0.2% to 2%, about 0.2% to 1 %, about 10.0% to 30%, about 15.0% to 30%, about 20.0% to 30%, about 10% to 20%, about 10% to 15%, about 15% to 20%, about 15% to 60%, about 20% to 60%, about 50% to 60%, and about 45% to 55% by weight.
  • the composition comprises an Al AR agonist in a concentration of about 0.25%, about 0.33%, about 0.5%, about 1%, about 2%, about 2.5%, about 3.0%, about 4.0%, about 5%, about 10%, about 15%, about 20%, or about 25% by weight.
  • the composition comprises a TAAR agonist in a concentration of about 0.25%, about 0.33%, about 0.5%, about 1%, about 2%, about 2.5%, about 3.0%, about 4.0%, about 10%, about 15%, about 20%, or about 25% by weight.
  • compositions used in the present disclosure may be formulated with a preservative such as EDTA (0.1-0.5% by weight of the formulation) and/or sodium metabisulfite (0.1-0.5% by weight of the formulation).
  • the composition includes a penetration enhancer, such as a penetration enhancer selected from one or more of the group consisting of alcohols, glycols, fatty acids, fatty esters, fatty ethers, occlusive agents, surface active agents, dimethylaminopropionic acid derivatives, terpenes, sulfoxides, cyclic ethers, amides, and amines.
  • a penetration enhancer such as a penetration enhancer selected from one or more of the group consisting of alcohols, glycols, fatty acids, fatty esters, fatty ethers, occlusive agents, surface active agents, dimethylaminopropionic acid derivatives, terpenes, sulfoxides, cyclic ethers, amides, and amines.
  • the composition may be packaged in a kit with an applicator for application to the skin.
  • the invention is also directed to a kit comprising a composition of the therapeutic agent, such as a combination of a TAAR agonist and an A1AR agonist, and an applicator, and to a kit comprising a composition of the therapeutic agent, such as a combination of a TAAR agonist and an Al AR agonist, and a hair brush or comb, particularly a brush or comb that provides exfoliating effect on the scalp such that there is light abrasion after its use that enhances penetration of the therapeutic agent to the AP muscle.
  • the therapeutic agent is provided in a metered dose applicator that provides for a fixed volume of the composition to be administered with each administration, such as 1 ml of the topical composition per administration.
  • Al AR agonists can be utilized including, phenylephrine, cirazoline, desvenlafaxine, etilfrine, metaraminol, methoxamine, naphazoline, oxymetazoline, pseudoephrine, m-synephrine, p-synephrine, synephrine, octopamine, hordenine, tetrahydrozoline, isometheptene, metaraminol, nicergoline, ergonovine, levonordefrin, phendimetrazine, methoxamine, midodrine, clonidine, pergolide, xylometazoline, droxidopa, epinephrine, mephentermine, 4-methoxyamphetamine, Benzphetamine
  • derivatives of TAAR agonists and/or Al AR agonists can be utilized including derivatives of the compounds mentioned above.
  • a prodrug that is activated to become a TAAR agonist and/or an Al AR agonist can be utilized.
  • midodrine is one such prodrug.
  • a particular prodrug can be activated by endogenous enzymes in the scalp such as Caspase-1 when follicular inflammation is present, e.g., at the location of application of a hair extension.
  • the TAAR agonist is tyramine and the Al AR agonist is synephrine.
  • the Al ARA is phenylephrine or synephrine, including compositions comprising the 1-enantiomer of synephrine, which is R-(-)-4-[l -hydroxy - 2-(methylamino)ethyl]phenol, that are essentially free of other enantiomers of synephrine, or in which less than 30%, 25%, 20%, 15%, 10%, 12%, 5%, 3%, 1%, or 0.5% by weight of the synephrine present in the composition is a different enantiomer.
  • the synephrine enantiomer R-(- )-4-[l-hydroxy-2-(methylamino)ethyl]phenol may be obtained from natural bitter orange extract.
  • the therapeutic agent is derived from bitter orange, Citrus aurantium, or is an extract of bitter orange, such as a bitter orange extract that contains 95%, 96%, 97%, 98%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% by weight or from 5-10%, 10-15%, 5-15%, 20-25%, 15-20%, 25-30%, 30-35%, 35-40%, 40-45%, 45-55%, 50- 60%, 60-70%, 70-80%, 80-90%, 85-95%, or 90-99% of one enantiomer of synephrine, R-(-)-4-[l- hydroxy-2-(methylamino)ethyl]phenol.
  • an extract of bitter orange such as a bitter orange extract that contains 95%, 96%, 97%, 98%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 9%, 8%, 7%, 6%,
  • Extracts of bitter orange contain high levels of only one synephrine enantiomer, namely, R-(-)-4-[l -hydroxy -2-(methylamino)ethyl]phenol, and are preferred for use in the present methods and compositions of the disclosure.
  • the compositions of the present invention contain 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 16%, 27%, 28%, 29%, 30% or 31% by weight of bitter orange extract, such as an extract that contains 3-5%, 5-10%, 6%, 9%, 10-15%, 15-20%, 20- 40%, 40-60%, 60-80%, or 80-95% synephrine, or the composition contains from about 5-10%, 10- 15%, 15-20%, 25-30% or 30-40% by weight of bitter orange extract, such as an extract containing from about 3-5%, 5-10%, 6%, 9%, 10-15%, 15-20%, 20-30%, 30-50%, 50-60%, 60-70%, 70-80%, 80-90% or 80-99% synephrine.
  • bitter orange extract such as an extract that contains 3-5%, 5-10%, 6%, 9%, 10-15%, 15-20%, 20-30%, 30-50%, 50-60%,
  • compositions of the present invention contain 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 16%, 27%, 28%, 29%, 30% or 31% by weight of a bitter orange extract, wherein the extract contains 50-90%, 50-60%, 60-70%, 70-80%, 80-90%, 85-95% or 90-99% synephrine and substantially all of the synephrine in the extract is the enantiomer R-(-)-4-[l-hydroxy-2- (m ethyl amino)ethy 1 ] phenol .
  • TAAR agonists can be utilized including citrus aurantium (e.g. bitter orange extract), 2-phenylethylamine, tyramine,p-tyramine, m-tyramine, N-methyltyramine, tryptamine, octopamine, m-octopamine, p- octopamine, ractopamine, dopamine, 5HT, 3 -methoxy -tyramine, trimethylamine, dimethylethylamine, N-methylpiperidine, 3-iodothyronamined, N,N-dimethylcyclohexyl amine, isoamylamine, cycl ohexyl 15 amine, serotonin, 3-methoxytyramine, amphetamine-like, amphetamine, methamphetamine, MDMA,
  • citrus aurantium e.g. bitter orange extract
  • 2-phenylethylamine e.g. bitter orange extract
  • TAAR agonists can be found at: Mark D. Berry, et al. Pharmacology of Human Trace Amine-associated Receptors: Therapeutic Opportunities and Challenges. Pharmacology & Therapeutics 18 (2017) 161-180, the entire contents of which is incorporated herein by reference in its entirety. Additionally, derivatives of TAAR agonists can be utilized including derivatives of the compounds mentioned above. In other embodiments, a prodrug that is activated to become a TAAR agonist can be utilized. For example, midodrine is one such prodrug. A particular prodrug can be activated by endogenous enzymes in the scalp such as Caspase-1 when follicular inflammation is present, e.g., at the location of application of a hair extension.
  • the TAAR agonist is octopamine.
  • the TAAR is pheny ethyl amine or octopamine, including compositions comprising the 1 -enantiomer of octopamine, that are essentially free of other enantiomers of octopamine, or in which less than 30%, 25%, 20%, 15%, 10%, 12%, 5%, 3%, 1%, or 0.5% by weight of the octopamine present in the composition is a different enantiomer.
  • the octopamine enantiomer R-(-)-4-(2-aminol- hydroxyethyl)phenol may be obtained from natural bitter orange extract.
  • a topically applied TAAR agonist is selected among : Morpholines, Fenbutrazate, Morazone, Phendimetrazine, Phenmetrazine, Oxazolines, Aminorex, Clominorex, Cyclazodone, Fenozolone, Fluminorex 4-Methylaminorex, Pemoline, Thozalinone, Phenethylamines, 2-OH-PEA, 4-CAB, 4-FA, 4-FMA, 4-MA, 4-MMA, Alfetamine, Amfecloral, Amfepentorex, Amfepramone, Amphetamine, dextroamphetamine, levoamphetamine, Amphetaminil, 0-Me-PEA, BDB, Benzphetamine, BOH, Buphedrone, Butylone, Cathine, Cathinone, Clobenzorex, Clortermine, D-Deprenyl, Dim ethyl amp
  • the TAAR agonist is tyramine, or a pharmaceutically acceptable salt or hydrate thereof.
  • Other agents can be 4-(2-Aminoethyl)phenol, 51-67-2, 4- Hydroxyphenethylamine, P-Tyramine, 2-( 4-Hydroxyphenyl) ethyl amine, Hydroxyphenethylamine, 4-(2-Aminoethyl) phenol, 4-Hydroxyphenethylamine, p-Tyramine, para-Tyramine, Tyramine, 4-(2-Aminoethyl)phenol, 51-67-2, 4-Hydroxyphenethylamine, p- Tyramine, 2-( 4-Hydroxyphenyl) ethylamine, Uteramine, Tyramin, Tyrosamine, Tocosine, 4- Hydroxyphenylethylamine, Systogene, Phenol, 4-(2-aminoethyl)-p-
  • the TAAR agonist is octopamine or tyramine, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 0.25% to 40%, 0.25% to 25% by weight, or 0.5% to 22.5% by weight, or 0.75% to 20% by weight, or 1% to 17.5% by weight, or 1.5% to 15% by weight, or 2% to 14.5% by weight, or 2.5% to 14% by weight, or 5% to 13.5% by weight, or 7.5% to 12.5% by weight, or 8% to 12% by weight, or 8.5% to 11.5% by weight, or 9% to 11% by weight, or 9.25% to 10.75% by weight, or 9.5% to 10.5% by weight, or 9.6% to 10.4% by weight, or 9.7% to 10.3% by weight, or 9.8% to 10.2% by weight, or 9.9% to 10.1 % by weight, or 9.95% to 10.05% by weight, or 9.96% to 10.04% by weight, or 9.97% to 10.03% 50 by weight, or 9.
  • the TAAR agonist is octopamine or tyramine, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration at a range of 0.25%, 0.5%, 0.75%, 1%, 1.5%, 2%, 2.5%, 5%, 7.5%, 8%, 8.5%, 9%, 9.25%, 9.5%, 9.6%,
  • the TAAR agonist is octopamine or tyramine, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 0.25% by weight, or 0.5% by weight, or 0.75% by weight, or 1 % by weight, or 1.5% by weight, or 2% by weight, or 2.5% by weight, or 5% by weight, or 7.5% by weight, or 8% by weight, or 8.5% by weight, or 9% by weight, or 9.25% by weight, or 9.5% by weight, or 9.6% by weight, or 9.7% by weight, or 9.8% by weight, or 9.9% by weight, or 9.95% by weight, or 9.96% by weight, or 9.97% by weight, or 9.98% by weight, or 9.99% by weight, or 10% by weight, or 10.01% by weight, or 10.02% by weight, or 10.03% by weight, or 10.04% by weight, or 10.05% by weight, or 10.1% by weight, or 10.2% by weight, or 10.3% by weight, or 10.4% by weight
  • the composition comprises a TAAR agonist that is octopamine or tyramine, or a pharmaceutically acceptable salt or hydrate thereof, or that comprises one enantiomer of octopamine or tyramine, namely R-(-)-4-(2-amino-l-hydroxyethyl)phenol and is substantially free of other enantiomer(s) of octopamine or has less than 30%, 25%, 20%, 15%, 10%, 12%, 5%, 3%, 1%, or 0.5% by weight of the octopamine or tyramine present in the composition as a different enantiomer, wherein the octopamine or tyramine is present in the composition in a concentration of 30% to 70% by weight, or 35% to 65% by weight, or 37.5% to 62.5% by weight, or 40% to 60% by weight, or 42.5% to 57.5% by weight, or 45% to 55% by weight, or 45.5% to 54.5%
  • the composition comprises a TAAR agonist that is octopamine or tyramine, or a pharmaceutically acceptable salt or hydrate thereof, or that comprises one enantiomer of octopamine or tyramine, namely R-(-)-4-(2-amino-l-hydroxyethyl)phenol and is substantially free of other enantiomer(s) of octopamine or tyramine or has less than 30%, 25%, 20%, 15%, 10%, 12%, 5%, 3%, 1%, or 0.5% by weight of the octopamine present in the composition as a different enantiomer, wherein the octopamine or tyramine is present in the composition in a concentration of 20% by weight, or 25% by weight, or 30% by weight, or 35% by weight, or 37.5% by weight, or 40% by weight, or 42.5% by weight, or 45% by weight, or 45.5% by weight, or 46% by weight, or 46.5% by
  • the composition comprises a TAAR agonist that is R-(-)-4-(2- amino-l-hydroxyethyl)phenol substantially free of the other enantiomer of octopamine or tyramine ( or having less than 25%, 20%, 15%, 10%, 5%, 1 % or 0.1 % of the other enantiomer of octopamine or tyramine) or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 20% by weight, or 21 % 10 by weight, or 25% by weight, or 26% by weight, or 30% by weight, or 35% by weight, or 37.5% by weight, or 40% by weight, or 42.5% by weight, or 45% by weight, or 45.5% by weight, or 46% by weight, or 46.5% by weight, or 47% by 15 weight, or 47.5% by weight, or 48% by weight, or 48.25% by weight, or 48.5% by weight, or 48.75% by weight, or 49% by weight
  • the composition comprises a TAAR agonist that is octopamine or tyramine, or a pharmaceutically acceptable salt or hydrate thereof, or that comprises one enantiomer of octopamine or tyramine, namely R-(-)-4-(2-amino-l-hydroxyethyl)phenol and is substantially free of other enantiomer(s) of octopamine or tyramine or has less than 30%, 25%, 20%, 15%, 10%, 12%, 5%, 3%, 1%, or 0.5% by weight of the octopamine present in the composition as a different enantiomer, wherein the octopamine or tyramine is present in the composition in a concentration of 10% to 60% by weight, or 12.5% to 50% by weight, or 10% to 50% by weight, or 15% to 40% by weight, or 20% to 30% by weight, or 20% to 40% by weight, or 17 .5% to 30% by weight, or 20% to 25% by weight, or 20.5%
  • the composition comprises a TAAR agonist that is octopamine or tyramine, or a pharmaceutically acceptable salt or hydrate thereof, or that comprises one enantiomer of octopamine or tyramine, namely R-(-)-4-(2-amino-l-hydroxyethyl)phenol and is substantially free of other enantiomer(s) of octopamine or tyramine or has less than 30%, 25%, 20%, 15%, 10%, 12%, 5%, 3%, 1%, or 0.5% by weight of the octopamine present in the 55 composition as a different enantiomer, wherein the octopamine or tyramine is present in the composition in a concentration of 10% by weight, or 12.5% by weight, or 15% by weight, or 17.5% by weight, or 20% by weight, or 20.5% by weight, or 21 % by weight, or 21.5% by weight, or 60 21.75% by weight, or 22% by weight, or
  • the TAAR agonist is phenylethylamine, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 0.01 % to 2% by weight, or 0.02% to 1.75% by weight, or 0.03% to 1.5% by weight, or 0.04% to 1.25% by weight, or 0.05% to 1 % by weight, or 0.1% to 0.9% by weight, or 0.15% to 0.85% by weight, or 0.2% to 0.8% by weight, or 0.25% to 0.75% by weight, or 0.3% to 0.7% by weight, or 0.35% to 0.65% by weight, or 0.4% to 0.6% by weight, or 0.41 % to 0.59% by weight, or 0.42% to 0.58% by weight, or 0.43% to 0.57% by weight, or 0.44% to 0.56% by weight, or 0.45% to 0.55% by weight, or 0.46% to 0.54% by weight, or 0.47% to 0.53% by weight, or 0.48% to 0.52% by weight,
  • the TAAR agonist is phenylethylamine, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 0.01 % by weight, or 0.02% by weight, or 0.03% by weight, or 0.04% by weight, or 0.05% by weight, or 0.1 % by weight, or 0.15% by weight, or 0.2% by weight, or 0.25% by weight, or 0.3% by weight, or 0.35% by weight, or 0.4% by weight, or 0.41 % by weight, or 0.42% by weight, or 0.43% by weight, or 0.44% by weight, or 0.45% by weight, or 0.46% by weight, or 0.47% by weight, or 0.48% by weight, or 0.49% by weight to 0.51 % by weight, or 0.52% by weight, or 0.53% by weight, or 0.54% by weight, or 0.55% by weight, or 0.56% by weight, or 0.57% by weight, or 0.58% by weight, or 0.59% by weight,
  • the TAAR is phenylethylamine, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 0.01 % by weight, or 0.02% by weight, or 0.03% by weight, or 0.04% by weight, or 0.05% by weight, or 0.1 % by weight, or 0.15% by weight, or 0.2% by weight, or 0.25% by weight, or 0.3% by weight, or 0.35% by weight, or 0.4% by weight, or 0.41% by weight, or 0.42% by weight, or 0.43% by weight, or 0.44% by weight, or 0.45% by weight, or 0.46% by weight, or 0.47% by weight, or 0.48% by weight, or 0.49% by weight, or 0.5% by weight, or 0.51 % by weight, or 0.52% by weight, or 0.53% by weight, or 0.54% by weight, or 0.55% by weight, or 0.56% by weight, or 0.57% by weight, or 0.58% by weight, or 0.5
  • the A1AR agonist is phenylephrine, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 0.25% to 40%, 0.25% to 25% by weight, or 0.5% to 22.5% by weight, or 0.75% to 20% by weight, or 1% to 17.5% by weight, or 1.5% to 15% by weight, or 2% to 14.5% by weight, or 2.5% to 14% by weight, or 5% to 13.5% by weight, or 7.5% to 12.5% by weight, or 8% to 12% by weight, or 8.5% to 11.5% by weight, or 9% to 11% by weight, or 9.25% to 10.75% by weight, or 9.5% to 10.5% by weight, or 9.6% to 10.4% by weight, or 9.7% to 10.3% by weight, or 9.8% to 10.2% by weight, or 9.9% to 10.1% by weight, or 9.95% to 10.05% by weight, or 9.96% to 10.04% by weight, or 9.97% to 10.03% by weight, or 9.98% to 10.02% by weight, or 9.9% to 10.
  • the A1AR agonist is phenylephrine, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration at a range of 0.25%, 0.5%,
  • the A1AR agonist is phenylephrine, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 0.25% by weight, or 0.5% by weight, or 0.75% by weight, or 1% by weight, or 1.5% by weight, or 2% by weight, or 2.5% by weight, or 5% by weight, or 7.5% by weight, or 8% by weight, or 8.5% by weight, or 9% by weight, or 9.25% by weight, or 9.5% by weight, or 9.6% by weight, or 9.7% by weight, or 9.8% by weight, or 9.9% by weight, or 9.95% by weight, or 9.96% by weight, or 9.97% by weight, or 9.98% by weight, or 9.99% by weight, or 10% by weight, or 10.01% by weight, or 10.02% by weight, or 10.03% by weight, or 10.04% by weight, or 10.05% by weight, or 10.1% by weight, or 10.2% by weight, or 10.3% by weight, or 10.4% by weight, or 10.5%
  • the composition comprises an A1AR agonist that is synephrine, or a pharmaceutically acceptable salt or hydrate thereof, or that comprises one enantiomer of synephrine, namely R-(-)-4-[l-hydroxy-2-(methylamino)ethyl]phenol and is substantially free of other enantiomer(s) of synephrine or has less than 30%, 25%, 20%, 15%, 10%, 12%, 5%, 3%, 1%, or 0.5% by weight of the synephrine present in the composition as a different enantiomer, wherein the synephrine is present in the composition in a concentration of 30% to 70% by weight, or 35% to 65% by weight, or 37.5% to 62.5% by weight, or 40% to 60% by weight, or 42.5% to 57.5% by weight, or 45% to 55% by weight, or 45.5% to 54.5% by weight, or 46% to 54% by weight, or 46.5% to 53.5% by weight
  • the composition comprises an A1AR agonist that is synephrine, or a pharmaceutically acceptable salt or hydrate thereof, or that comprises one enantiomer of synephrine, namely R-(-)-4-[l-hydroxy-2-(methylamino)ethyl]phenol and is substantially free of other enantiomer(s) of synephrine or has less than 30%, 25%, 20%, 15%, 10%, 12%, 5%, 3%, 1%, or 0.5% by weight of the synephrine present in the composition as a different enantiomer, wherein the synephrine is present in the composition in a concentration of 20% by weight, or 25% by weight, or 30% by weight, or 35% by weight, or 37.5% by weight, or 40% by weight, or 42.5% by weight, or 45% by weight, or 45.5% by weight, or 46% by weight, or 46.5% by weight, or 47% by weight, or 47.5% by weight, or 48% by weight, or
  • the composition comprises an A1AR agonist that is R-(-)-4- [l-hydroxy-2-(methylamino)ethyl]phenol substantially free of the other enantiomer of synephrine (or having less than 25%, 20%, 15%, 10%, 5%, 1% or 0.1% of the other enantiomer of synephrine) or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 20% by weight, or 21% by weight, or 25% by weight, or 26% by weight, or 30% by weight, or 35% by weight, or 37.5% by weight, or 40% by weight, or 42.5% by weight, or 45% by weight, or 45.5% by weight, or 46% by weight, or 46.5% by weight, or 47% by weight, or 47.5% by weight, or 48% by weight, or 48.25% by weight, or 48.5% by weight, or 48.75% by weight, or 49% by weight, or 49.25% by weight, or 49.5% by weight, or 49.5% by
  • the composition comprises an A1AR agonist that is synephrine, or a pharmaceutically acceptable salt or hydrate thereof, or that comprises one enantiomer of synephrine, namely R-(-)-4-[l-hydroxy-2-(methylamino)ethyl]phenol and is substantially free of other enantiomer(s) of synephrine or has less than 30%, 25%, 20%, 15%, 10%, 12%, 5%, 3%, 1%, or 0.5% by weight of the synephrine present in the composition as a different enantiomer, wherein the synephrine is present in the composition in a concentration of 10% to 60% by weight, or 12.5% to 50% by weight, or 10% to 50% by weight, or 15% to 40% by weight, or 20% to 30% by weight, or 20% to 40% by weight, or 17.5% to 30% by weight, or 20% to 25% by weight, or 20.5% to 24.5% by weight, or 21% to 24% by weight, or 21.5% to 23.5%
  • the composition comprises an A1AR agonist that is synephrine, or a pharmaceutically acceptable salt or hydrate thereof, or that comprises one enantiomer of synephrine, namely R-(-)-4-[l-hydroxy-2-(methylamino)ethyl]phenol and is substantially free of other enantiomer(s) of synephrine or has less than 30%, 25%, 20%, 15%, 10%, 12%, 5%, 3%, 1%, or 0.5% by weight of the synephrine present in the composition as a different enantiomer, wherein the synephrine is present in the composition in a concentration of 10% by weight, or 12.5% by weight, or 15% by weight, or 17.5% by weight, or 20% by weight, or 20.5% by weight, or 21% by weight, or 21.5% by weight, or 21.75% by weight, or 22% by weight, or 22.1% by weight, or 22.2% by weight, or 22.3% by weight, or 22.4% by
  • the composition comprises one enantiomer of synephrine, namely R-(-)-4-[l-hydroxy-2-(methylamino)ethyl]phenol, and is substantially free of other enantiomer(s) of synephrine or has less than 30%, 25%, 20%, 15%, 10%, 12%, 5%, 3%, 1%, or 0.5% by weight of the synephrine present in the composition as a different enantiomer, wherein the R-(-)-4-[l-hydroxy-2-(methylamino)ethyl]phenol is present in the composition in a concentration of 20% to 25% by weight.
  • the A1AR agonist is oxymetazoline, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 0.01% to 2% by weight, or 0.02% to 1.75% by weight, or 0.03% to 1.5% by weight, or 0.04% to 1.25% by weight, or 0.05% to 1% by weight, or 0.1% to 0.9% by weight, or 0.15% to 0.85% by weight, or 0.2% to 0.8% by weight, or 0.25% to 0.75% by weight, or 0.3% to 0.7% by weight, or 0.35% to 0.65% by weight, or 0.4% to 0.6% by weight, or 0.41% to 0.59% by weight, or 0.42% to 0.58% by weight, or 0.43% to 0.57% by weight, or 0.44% to 0.56% by weight, or 0.45% to 0.55% by weight, or 0.46% to 0.54% by weight, or 0.47% to 0.53% by weight, or 0.48% to 0.52% by weight, or 0.49% to a composition in a concentration of 0.0
  • the A1AR agonist is oxymetazoline, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 0.01% by weight, or 0.02% by weight, or 0.03% by weight, or 0.04% by weight, or 0.05% by weight, or 0.1% by weight, or 0.15% by weight, or 0.2% by weight, or 0.25% by weight, or 0.3% by weight, or 0.35% by weight, or 0.4% by weight, or 0.41% by weight, or 0.42% by weight, or 0.43% by weight, or 0.44% by weight, or 0.45% by weight, or 0.46% by weight, or 0.47% by weight, or 0.48% by weight, or 0.49% by weight to 0.51% by weight, or 0.52% by weight, or 0.53% by weight, or 0.54% by weight, or 0.55% by weight, or 0.56% by weight, or 0.57% by weight, or 0.58% by weight, or 0.59% by weight, or 0.6% by weight, or 0.6% by weight, or 0. 0.6% by
  • the A1ARA is oxymetazoline, or a pharmaceutically acceptable salt or hydrate thereof, in a composition in a concentration of 0.01% by weight, or 0.02% by weight, or 0.03% by weight, or 0.04% by weight, or 0.05% by weight, or 0.1% by weight, or 0.15% by weight, or 0.2% by weight, or 0.25% by weight, or 0.3% by weight, or 0.35% by weight, or 0.4% by weight, or 0.41% by weight, or 0.42% by weight, or 0.43% by weight, or 0.44% by weight, or 0.45% by weight, or 0.46% by weight, or 0.47% by weight, or 0.48% by weight, or 0.49% by weight, or 0.5% by weight, or 0.51% by weight, or 0.52% by weight, or 0.53% by weight, or 0.54% by weight, or 0.55% by weight, or 0.56% by weight, or 0.57% by weight, or 0.58% by weight, or 0.59% by weight, or 0.6%
  • a combination of a TAAR agonist and an A1AR agonist formulated with a carrier or delivery vehicle optimized for delivery of the combination of the TAAR agonist and the Al AR agonist to the scalp.
  • a combination of a TAAR agonist and an A1AR agonist can be released using several different formulations or release methods including time release, creams, ointments, sprays, capsules, or other release methods.
  • the combination of the TAAR agonist and the A1AR agonist can be incorporated into a shampoo for utilization during showering so that when a user brushes their hair, their follicles will be tightly held by the AP muscles to prevent brushing from unnecessarily pulling out healthy hair.
  • the combination of the TAAR agonist and the A1AR agonist can be included in ointments or other topical creams that could be applied to the scalp so that it can be slowly absorbed into the skin and stimulate the smooth muscle.
  • the combination of the TAAR agonist and the A1AR agonist can be included in a liquid spray or aerosol medium to be applied to the scalp.
  • the combination of the TAAR agonist and the Al AR agonist can be incorporated into capsules or other slow release vehicles that would allow the chemical or agent to be slowly released into the dermis of the scalp.
  • Capsules or vehicles that encapsulate the combination of the TAAR agonist and the Al AR agonist can include, but are not limited to, liposomes, non-ionic liposomes, niosomes, novasome I, erythromycin-Zn complex, microspheres, nanoparticles, solid lipid nanoparticles, and nanoemulsions. In some embodiments, this can include a gel or foam that is applied to the scalp. It is specifically contemplated that the combination of the TAAR agonist and the Al AR agonist can be formulated in hair care products such as styling gel, styling foam, hair conditioner, hair serum, a hair mask, etc.
  • any of the aforementioned combinations of TAAR agonists and A1AR agonists can be applied by a user before the application of a hair extension device or other device or condition that exerts force on the hair follicle.
  • a combination of a TAAR agonist and an Al AR agonist can be used routinely (e.g. twice daily) after such a device has been installed. Routine use of a combination of a TAAR agonist and an Al AR agonist would be indicated as a prophylactic against traction alopecia for users of a hair extension device or other device that exerts force on the hair follicle.
  • Creams or other formulations with different combinations of TAAR agonists and/or Al AR agonists can be applied prior to a user utilizing a hair piece or brushing the hair.
  • a hair piece or hair extensions can contain pads or other absorbent material that can absorb TAAR agonists and/or Al AR agonists in a foam or cream applied prior to application to a user’s head.
  • slow release capsules can be incorporated into the hair extensions or hair pieces, or can be included in barrettes.
  • barrettes will include pads with an absorbent layer for application of a TAAR agonist and/or Al AR agonist cream or other TAAR agonist and/or Al AR agonist topical formulation.
  • Efficacy of treatment to treat or prevent traction alopecia can be determined by monitoring the density of hairs on a given area of the subject’s body, e.g., a given area of the scalp. If the rate of hair loss is reduced, e.g., by 10% or more following treatment, the treatment is effective for the prevention of traction alopecia. Similarly, if hair density remains the same, despite ongoing traction that would normally have been expected to cause traction alopecia, the treatment is effective for the prevention of traction alopecia. If the density of hair increases, e.g., by 5% or more, e.g., by 10% or more following treatment and despite ongoing traction, the treatment is also considered effective for the treatment and/or prevention of traction alopecia.
  • alopecia can benefit from the technology described herein.
  • the technology described herein can be applicable to prevent or treat androgenic alopecia.
  • the AP muscle degenerates in the process of androgenic alopecia (reviewed, e.g., in Torkamani et al., Int. J. Trichology 6:88-94 (2014)); without wishing to be bound by theory, it is contemplated that regular stimulation of AP muscle contraction may slow or reduce the loss of the muscle and thereby benefit the treatment or prevention of androgenic alopecia.
  • the technology described herein can be broadly applicable to any type of condition of which at least one hair follicle is under tension. Using the combination of TAAR and Al AR agonist compositions or other agents that stimulate AP muscle contraction as described herein, it is contemplated that one can limit or reduce hair shedding under such conditions.
  • the condition of which at least one hair follicle is under tension is brushing or combing.
  • the technology described herein relates to a method of reducing hair shedding during brushing or combing.
  • reducing hair shedding means that the amount of hair shedding from a subject is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or more, as compared to what would be expected in the absence of the method.
  • a combination of a TAAR agonist and an A1AR agonist or other agent that stimulates AP muscle contraction can be present on the brush or comb used for the brushing or combing.
  • the combination of the TAAR agonist and the Al AR agonist or other agent can be applied to the brush or comb prior to brushing or combing, e.g., in the form of a liquid, gel, cream or spray.
  • the brush or comb can dispense the combination of the TAAR agonist and the Al AR agonist or other agent.
  • Agents that promote the contraction of the AP muscle can optionally be administered by iontophoresis, which uses an electric field to drive the passage of ionic agents or drugs into the skin.
  • iontophoresis has been used to deliver agents such as phenylephrine to the skin to stimulate AP muscle contraction (See, e.g., Siepmann et al., Neurology April 25, 2012; 78(Meeting Abstracts 1): P05.197).
  • a brush or comb can incorporate an iontophoresis device, which can dispense the combination of the TAAR agonist and the Al AR agonist or other agent and/or be used for transdermal delivery of the agent(s).
  • the iontophoresis device can comprise one or more metal contacts.
  • the iontophoresis device can comprise one or more compartments for containing the combination of the TAAR agonist and the Al AR agonist or other agent(s).
  • the condition in which at least one hair follicle is under tension is a hair-related cosmetic procedure.
  • the technology described herein relates to a method of reducing hair shedding during a hair-related cosmetic procedure.
  • hair- related cosmetic procedures include, but are not limited to, brushing, braiding, flat ironing, and combinations thereof.
  • the condition in which at least one hair follicle is under tension is trichotillomania, a disorder characterized by the compulsive urge to pull out one's hair. Accordingly, to the extent that increasing the force required to remove the hair can help counter hair loss due to this condition, the stimulation of AP muscle contraction as described herein can provide a method to reduce the hair loss. Electrical stimulation
  • the AP muscle can be contracted via electrical stimulation to the scalp or dermis of the skull.
  • the electrical stimulation can be controlled, e.g., by a unit contained in a brush or a comb, or, e.g., embedded in a hair extension.
  • the control unit can contain an accelerometer to detect the optimal time to contract the AP muscles based on the posture of the subject or the subject’s hair.
  • a strain or other force gauge attached to a portion of a hair extension can test the force pulling on the patient’s hair.
  • the electrical stimulator could vary the amount of current, voltage or other component of the electrical stimulation applied to vary the strength of smooth muscle contraction based on the amount of force pulling on the hair at a certain time.
  • the control unit can deliver a standard amount of current to the hair in order to reach the electrical threshold for contraction of the AP muscle. This can advantageously minimize the amount of current being applied to the scalp overall and the amount of electricity. Accordingly, one advantage of utilizing electrical stimulation to contract the muscle, is that the strength of the contraction can be varied accordingly.
  • the voltage or amplitude of the signal applied to the scalp can be in the range of 35 to 75 volts, 25 to 50 volts, 10 - 30 volts or other suitable ranges to reach the threshold for muscle contraction.
  • the current applied to a scalp by a device as disclosed herein can, in some embodiments, preferably be in the microamps to avoid electrocution of the user.
  • a frequency of 10 KHz to 15 KHz can be applied, or a lower or higher frequency.
  • the pulse length applied will be from 1 to 50 milliseconds, 1 to 100 milliseconds, or other suitable lengths to contract the AP muscle or any other pilomotor effective amount of current.
  • a control unit will automatically pulse the electrical stimulation at random intervals that are enough to keep the AP muscle relatively contracted. In other embodiments, the pulses will be spaced out enough to allow the AP muscle to relax in between pulses.
  • the disclosure also concerns a device for hair augmentation and prevention of traction alopecia comprising: a hair augmentation device; and an electrical stimulation device connected to the hair augmentation device, the electrical stimulation device comprising: a battery; a memory; an electrical stimulation generator; a scalp probe in electrical communication with the electrical stimulation generator for applying an electrical stimulus; and a controller in communication with the battery, memory, and electrical stimulation and memory wherein the controller commands the electrical stimulus generator to output a pilomotor effective amount of electrical stimulus.
  • the pilomotor effective amount of electrical stimulus is between 10 - 100 volts, or between 10 - 15 kHz.
  • the pilomotor effective amount of electrical stimulus is applied for 1 to 100 milliseconds.
  • the pilomotor effective amount of electrical stimulus is applied periodically with rest periods long enough to allow the AP muscle to relax between stimuli. In other embodiments, the pilomotor effective amount of electrical stimulus is applied periodically with rest periods short enough to prevent the AP muscle from relaxing between stimuli.
  • the hair augmentation device may be any product that when applied to the hair exerts a pulling force on the hair.
  • the hair augmentation device may be a hair extension, a weave, or a barrette.
  • a probe or electrical prongs can be attached to a hair extension or other hair piece that would deliver the charge to the scalp.
  • the probe can be connected to a control unit with an on switch, a processor, and memory with firmware or other software instructions for delivering the desired pulses.
  • Different control units can contain more advanced circuitry and algorithms for processing accelerometer or force data and varying the electrical stimulus accordingly.
  • the probe can be connected to any portion of a hair piece using any suitable apparatus and method.
  • the smooth muscle can be contracted by stimulating or activating a cold receptor.
  • a cold receptor can be stimulated, for example, by activating the TRPM8 channel.
  • agents that can stimulate a cold receptor include, but are not limited to, menthol and icilin. Compositions and methods for stimulating a cold receptor are disclosed, for example, in US Patent 4,034,109, the contents of which are incorporated by reference in its entirety.
  • agents that stimulate release of transmitters from these systems can be used to stimulate AP muscle contraction.
  • trace amine associated receptor agonists and/or alpha 1 adrenergic agonists but also cholinergic agonists, including, but not limited to acetylcholine and other neurotransmitters that stimulate smooth muscle contraction are contemplated for use in the methods and compositions described herein.
  • the alpha 1 adrenergic receptor is a G protein-coupled receptor. Agonists of other G protein-coupled receptors (e.g., alpha 2 adrenergic receptor) can also be used to stimulate contraction of the smooth muscle.
  • G protein-coupled receptors e.g., alpha 2 adrenergic receptor
  • alpha 2 adrenergic receptor agonists include, but are not limited to, 4-NEMD, 7-Me-marsanidine, agmatine, apraclonidine, brimonidine, clonidine, detomidine, dexmedetomidine, fadolmidine, guanabenz, guanfacine, lofexidine, marsanidine, medetomidine, methamphetamine, mivazerol, rilmenidine, romifidine, talipexole, tizanidine, tolonidine, xylazine, and xylometazoline.
  • 4-NEMD 7-Me-marsanidine
  • agmatine apraclonidine
  • brimonidine clonidine
  • detomidine dexmedetomidine
  • fadolmidine dexmedetomidine
  • guanabenz guanfacine
  • halostachine also known as N- methylphenylethanolamine
  • halostachine is contemplated for use as a therapeutic agent in the methods and compositions described herein to stimulate smooth muscle contraction.
  • agonists described herein also encompass their inorganic or organic salts.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, succinate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
  • compositions described herein can also be used for the treatment of acne. It is known that contraction of the AP muscle plays a role in the secretion of the sebum (see Mahfouz et al., J. Egyptian worn. Dermatol. Soc. 2005, 2, 25-29).
  • the compositions can be applied in the form of lotion, cream, spray, or wipe.
  • the compositions can be used in combination with benzoyl peroxide or other topical medications for acne treatment.
  • Example 1 Oxymetazoline HC1 at 0.1%, 0.2%, 0.5% by weight
  • Figures 2 and 3 show that application of the 10% phenylephrine hydrochloride solution resulted in reduced hair shedding in 80% of the patients, as compared to the placebo solution containing the vehicle, with the average reduction being approximately 42%.
  • Figures 4 and 5 show that the epliatory force threshold for plucking hair follicles following topical 10% phenylephrine hydrochloride application increased by approximately 172%. Therefore, there is a significant reduction hair loss from mechanical pulling and increase in epilatory force after topical application of 10% phenylephrine hydrochloride.
  • This novel study demonstrates the utility of al -AR agonists in the treatment of traction alopecia and excessive hair loss resulting from mechanical cosmetic procedures.
  • Patients Fifteen female subjects, ages 18-40, were included in the study. Subjects were recruited based on their frequent use of traumatic hair care practices, such as, tight braids, head scarves, ponytails, extensions, hair rollers, hair weaves and heated styling appliances such as blow dryers, flat irons, heat setters and curling irons. Subjects with uncontrolled hypertension, that were pregnant or breastfeeding, had been diagnosed with pattern hair loss or with other hair loss in conjunction with female pattern hair loss were excluded from the study. Prior to initiating the study, the efficacy of the 10% phenylephrine solution was tested by applying a small aliquot (50 pL) of the solution to the forearm of three subjects. Piloerection and blanching were visible after 30 minutes; the effect lasted for approximately 2-3 hours.
  • traumatic hair care practices such as, tight braids, head scarves, ponytails, extensions, hair rollers, hair weaves and heated styling appliances such as blow dryers, flat irons, heat setters and curling irons.
  • a hand-held spring dynamometer or "trichotillometer” was used (8).
  • the trichotillometer records the maximum force threshold, in grams, required to pluck a single hair from the scalp; the performance and statistical variance of the instrument have been reported previously (8-10). Force measurements were performed using the trichotillometer on 10 subjects. The frontal area of scalp was divided into two 8x10 cm2 areas. On the right side 0.5 mL of a placebo vehicle was applied. On the left side, 0.5 mL a 10% phenylephrine solution was applied. After 45 minutes, ten hairs were plucked from each of the target areas with the trichotillometer. RESULTS:
  • Example 7 Tyramine at 5.0%, 7.5%, 10% by weight
  • Example 8 Tyramine at 4.0% and Synephrine at 5% by weight
  • the 4.0% topical tyramine solution (Formula B) elicited a clinical response in 80% of subjects while the 2.0% formulation (Formula A) elicited a clinical response in 40% of subjects.
  • the 4.0% topical tyramine solution response in the contraction of the arrector-pilomotor muscle was obtained approximately within 2-5 minutes and lasted over 1 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode de traitement de l'alopécie de traction comprenant l'application d'une composition comprenant une quantité efficace de pilomoteur d'une combinaison de synéphrine et de tyramine, ou d'un sel ou hydrate pharmaceutiquement acceptable de celles-ci, par voie topique sur une partie de la peau sur la tête qui comprend au moins un follicule pileux pour augmenter le seuil de force épilatoire du ou des follicules pileux.
PCT/US2022/080540 2022-11-29 2022-11-29 Système et méthode pour la prévention de l'alopécie WO2024118094A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2022/080540 WO2024118094A1 (fr) 2022-11-29 2022-11-29 Système et méthode pour la prévention de l'alopécie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2022/080540 WO2024118094A1 (fr) 2022-11-29 2022-11-29 Système et méthode pour la prévention de l'alopécie

Publications (1)

Publication Number Publication Date
WO2024118094A1 true WO2024118094A1 (fr) 2024-06-06

Family

ID=84541363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/080540 WO2024118094A1 (fr) 2022-11-29 2022-11-29 Système et méthode pour la prévention de l'alopécie

Country Status (1)

Country Link
WO (1) WO2024118094A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034109A (en) 1973-01-18 1977-07-05 Wilkinson Sword Limited Compounds having a physiological cooling effect and compositions containing them
US4853216A (en) 1987-04-02 1989-08-01 Bristol-Myers Company Process and composition for the topical application of alpha1 adrenergic agonist for pilomotor effects
US20090068287A1 (en) 2007-09-12 2009-03-12 Susan Welsh Novel topical formulations of flucytosine and uses thereof
US20130199348A1 (en) 2012-02-06 2013-08-08 David Aberizk Pilomotor effect stimulating device and method
WO2016077744A1 (fr) * 2014-11-14 2016-05-19 Goren Ofer A Système et procédé pour prévenir l'alopécie
WO2018218012A1 (fr) * 2017-05-24 2018-11-29 Follea International Compositions de synéphrine
WO2020023084A1 (fr) * 2018-07-26 2020-01-30 Applied Biology, Inc. Agonistes du récepteur taar pour le traitement de l'alopécie
KR20210157892A (ko) * 2020-06-22 2021-12-29 김병하 천연물질을 유효성분으로 포함하는 비만 예방 또는 치료를 위한 약제학적 조성물

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034109A (en) 1973-01-18 1977-07-05 Wilkinson Sword Limited Compounds having a physiological cooling effect and compositions containing them
US4853216A (en) 1987-04-02 1989-08-01 Bristol-Myers Company Process and composition for the topical application of alpha1 adrenergic agonist for pilomotor effects
US20090068287A1 (en) 2007-09-12 2009-03-12 Susan Welsh Novel topical formulations of flucytosine and uses thereof
US20130199348A1 (en) 2012-02-06 2013-08-08 David Aberizk Pilomotor effect stimulating device and method
WO2016077744A1 (fr) * 2014-11-14 2016-05-19 Goren Ofer A Système et procédé pour prévenir l'alopécie
WO2018218012A1 (fr) * 2017-05-24 2018-11-29 Follea International Compositions de synéphrine
WO2020023084A1 (fr) * 2018-07-26 2020-01-30 Applied Biology, Inc. Agonistes du récepteur taar pour le traitement de l'alopécie
KR20210157892A (ko) * 2020-06-22 2021-12-29 김병하 천연물질을 유효성분으로 포함하는 비만 예방 또는 치료를 위한 약제학적 조성물

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
CHASE ESWEINSIER RLLAVEN GTKRUMDIECK CL: "Trichotillometry: the quantitation of hair pluckability as a method of nutritional assessment", AM J CLIN NUTR, vol. 34, no. 10, 1981, pages 2280 - 2286
GOREN ANDY ET AL: "[alpha] 1 -AR agonist induced piloerection protects against the development of traction alopecia : [alpha] 1 -AR agonist induced piloerection", DERMATOLOGIC THERAPY, vol. 29, no. 3, 17 December 2015 (2015-12-17), US, pages 160 - 163, XP093057583, ISSN: 1396-0296, DOI: 10.1111/dth.12324 *
HELLMANN K: "The isolated pilomotor muscles as an in vitro preparation", J PHYSIOL, vol. 169, 1963, pages 603 - 620
HELLMANN, J. PHYSIOL., vol. 169, 1963, pages 603 - 620
HJORTH N: "Traumatic marginal alopecia; a special type: alopecia groenlandica", BR J DERMATOL, vol. 69, no. 9, 1957, pages 319 - 322
KHUMALO NPJESSOP SGUMEDZE FEHRLICH R: "Determinants of marginal traction alopecia in African girls and women", J AM ACAD DERMATOL, vol. 59, no. 3, 2008, pages 432 - 438, XP024518731, DOI: 10.1016/j.jaad.2008.05.036
KOVACEVIC MAJA ET AL: "Novel shampoo reduces hair shedding by contracting the arrector pili muscle via the trace amine-associated receptor", JOURNAL OF COSMETIC DERMATOLOGY, vol. 18, no. 6, 2 July 2019 (2019-07-02), GB, pages 2037 - 2039, XP093057550, ISSN: 1473-2130, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jocd.13054> DOI: 10.1111/jocd.13054 *
LEWIS TMARVIN HM: "Observations upon a pilomotor reaction in response to faradism", J PHYSIOL, vol. 64, no. 1, 1927, pages 87 - 106
MAHFOUZ ET AL., J. EGYPT WORN. DERMATOL. SOC., vol. 2, 2005, pages 25 - 29
MARK D. BERRY ET AL.: "Pharmacology of Human Trace Amine-associated Receptors: Therapeutic Opportunities and Challenges", PHARMACOLOGY & THERAPEUTICS, vol. 18, 2017, pages 161 - 180
OZCELIK D: "Extensive traction alopecia attributable to ponytail hairstyle and its treatment with hair transplantation", AESTHETIC PLAST SURG, vol. 29, no. 4, 2005, pages 325 - 327, XP035990379, DOI: 10.1007/s00266-005-0004-5
PIASCIK MTPEREZ DM: "Alphal-adrenergic receptors: new insights and directions", J PHARMACOL EXP THER, vol. 298, no. 2, 2001, pages 403 - 410, XP002259217
SIEPMANN ET AL., NEUROLOGY, vol. 78, 25 April 2012 (2012-04-25), pages 197
SIEPMANN TGIBBONS CHILLIGENS BMLAFO JABROWN CMFREEMAN R: "Quantitative pilomotor axon reflex test: a novel test of pilomotor function", ARCH NEUROL, vol. 69, no. 11, 2012, pages 1488 - 1492
SMELSER DNSMELSER NBKRUMDIECK CLSCHREEDER MTLAVEN GT: "Field use of hair epilation force in nutrition status assessment", AM J CLIN NUTR, vol. 35, 1982, pages 342 - 346
TORKAMANI ET AL., INT. J. TRICHOLOGY, vol. 6, 2014, pages 88 - 94
WYNESS LAMCNEILL GPRESCOTT GL: "Trichotillometry: the reliability and practicality of hair pluckability as a method of nutritional assessment", NUTR J, vol. 6, 2007, pages 9, XP021024236, DOI: 10.1186/1475-2891-6-9
ZEVEKEGLADYSHEVA, BULL. EXP. BIOL. MED., vol. 71, 1971, pages 102 - 105

Similar Documents

Publication Publication Date Title
EP3217967B1 (fr) Système et procédé pour prévenir l&#39;alopécie
US20210137854A1 (en) TAAR Receptor Agonists for the Treatment of Alopecia
US20060264515A1 (en) Compounds, formulations, and methods for ameliorating telangiectasias
JP2017533953A5 (fr)
US8986664B2 (en) Use of monoamine oxidase inhibitors to improve epithelial biology
CA2392620C (fr) Melatonine servant a traiter l&#39;alopecie androgenetique et diffuse
AU2011273510A1 (en) Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
TW202027720A (zh) 毛髮化妝品組合物
KR20200050944A (ko) 미용 조성물 및 사용 방법
WO2024118094A1 (fr) Système et méthode pour la prévention de l&#39;alopécie
US10758465B2 (en) Synephrine compositions
WO2018093370A1 (fr) Système et méthode pour la prévention de l&#39;alopécie
US9554988B2 (en) Method for preventing or treating skin tumor
JP2014512335A (ja) 毛髪成長を増強するための化合物および方法
JPS63135316A (ja) アルキレンジアミノキナゾリン誘導体に基づく毛髪の生長を誘発及び刺激し且つ脱毛を抑制するための組成物
AU2021395980A1 (en) Composition for hair improvement
WO2015075542A1 (fr) Remède pour arrêter la chute des cheveux